23 research outputs found
Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Venous malformations (VMs) are painful and deforming vascular lesions composed of dilated vascular channels, which are present from birth. Mutations in the TEK gene, encoding the tyrosine kinase receptor TIE2, are found in about half of sporadic (nonfamilial) VMs, and the causes of the remaining cases are unknown. Sclerotherapy, widely accepted as first-line treatment, is not fully efficient, and targeted therapy for this disease remains underexplored. We have generated a mouse model that faithfully mirrors human VM through mosaic expression of Pik3ca(H1047R), a constitutively active mutant of the p110α isoform of phosphatidylinositol 3-kinase (PI3K), in the embryonic mesoderm. Endothelial expression of Pik3ca(H1047R)resulted in endothelial cell (EC) hyperproliferation, reduction in pericyte coverage of blood vessels, and decreased expression of arteriovenous specification markers. PI3K pathway inhibition with rapamycin normalized EC hyperproliferation and pericyte coverage in postnatal retinas and stimulated VM regression in vivo. In line with the mouse data, we also report the presence of activating PIK3CA mutations in human VMs, mutually exclusive with TEK mutations. Our data demonstrate a causal relationship between activating Pik3ca mutations and the genesis of VMs, provide a genetic model that faithfully mirrors the normal etiology and development of this human disease, and establish the basis for the use of PI3K-targeted therapies in VMs.Postdoctoral fellowships were from EMBO (A LTF 165-2013) to S.D.C, EU Marie Curie (MEIF-CT-2005-010264) to E.T. and EU Marie Curie (PIIF-GA-2009-252846) to I.M.B. M.Z.-T. is supported by the EPSRC Early Career Fellowship of T.L.K. (EP/L006472/1). D.J.S. is a BHF Intermediate Basic Science Research Fellow (FS/15/33/31608). A.L.D is supported by the UK NIHR Joint UCL/University College London Hospitals Biomedical Research Centre. V.E.R.P. was supported by the Wellcome Trust (097721/Z/11/Z). R.K.S. is supported by the Wellcome Trust (WT098498), the Medical Research Council (M RC_MC_UU_12012/5). R.G.K. is supported by the NIHR Rare Diseases Translational Research Collaboration. V.W. is supported by the European FPVI Integrated Project ‘Eurostemcell’. M.F.L. and A.B. are supported by the King’s College London and UCL Comprehensive Cancer Imaging Centre CR-UK and EPSRC, in association with the MRC and DoH (England). W.A.P. is supported by funding from the National Health and Medical Research Council (NHMRC) of Australia. Work in the laboratory of M.G. is supported by research grants SAF2013-46542-P and SAF2014-59950-P from MICINN (Spain), 2014-SGR-725 from the Catalan Government, the People Programme (Marie Curie Actions) from the European Union's Seventh Framework Programme FP7/2007-2013/ (REA grant agreement 317250), the Institute of Health Carlos III (ISC III) and the European Regional Development Fund (ERDF) under the integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE). Work in the laboratory of B.V. is supported by Cancer Research UK (C23338/A15965) and the UK NIHR University College London Hospitals Biomedical Research Centre.This is the author accepted manuscript. The final version is available from the American Association for the Advancement of Science via http://dx.doi.org/10.1126/scitranslmed.aad998
Angiocrine polyamine production regulates adiposity.
Reciprocal interactions between endothelial cells (ECs) and adipocytes are fundamental to maintain white adipose tissue (WAT) homeostasis, as illustrated by the activation of angiogenesis upon WAT expansion, a process that is impaired in obesity. However, the molecular mechanisms underlying the crosstalk between ECs and adipocytes remain poorly understood. Here, we show that local production of polyamines in ECs stimulates adipocyte lipolysis and regulates WAT homeostasis in mice. We promote enhanced cell-autonomous angiogenesis by deleting Pten in the murine endothelium. Endothelial Pten loss leads to a WAT-selective phenotype, characterized by reduced body weight and adiposity in pathophysiological conditions. This phenotype stems from enhanced fatty acid β-oxidation in ECs concomitant with a paracrine lipolytic action on adipocytes, accounting for reduced adiposity. Combined analysis of murine models, isolated ECs and human specimens reveals that WAT lipolysis is mediated by mTORC1-dependent production of polyamines by ECs. Our results indicate that angiocrine metabolic signals are important for WAT homeostasis and organismal metabolism.We thank members of the Endothelial Pathobiology and Microenvironment Group for
helpful discussions. We thank the CERCA Program/Generalitat de Catalunya and the
Josep Carreras Foundation for institutional support. The research leading to these results
has received funding from la Fundación BBVA (Ayuda Fundacion BBVA a Equipos de
Investigación CientÃfica 2019, PR19BIOMET0061) and from SAF2017-82072-ERC from
Ministerio de Ciencia, Innovación y Universidades (MCIU) (Spain). The laboratory
of M.G. is also supported by the research grants SAF2017-89116R-P (FEDER/EU)
co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe
and PID2020-116184RB-I00 from MCEI; by the Catalan Government through the
project 2017-SGR; PTEN Research Foundation (BRR-17-001); La Caixa Foundation
(HR19-00120 and HR21-00046); by la Asociación Española contra el Cancer-Grupos
Traslacionales (GCTRA18006CARR, also to A.C.); European Foundation for the Study
of Diabetes/Lilly research grant, also to M.C.); and by the People Programme (Marie
Curie Actions; grant agreement 317250) of the European Union’s Seventh Framework
Programme FP7/2007-2013 and the Marie Skłodowska-Curie (grant agreement 675392)
of the European Union’s Horizon 2020 research. The laboratory of A.C. is supported by
the Basque Department of Industry, Tourism and Trade (Elkartek) and the department
of education (IKERTALDE IT1106-16), the MCIU (PID2019-108787RB-I00 (FEDER/
EU); Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks
SAF2016-81975-REDT), La Caixa Foundation (ID 100010434), under the agreement
LCF/PR/HR17, the Vencer el Cancer foundation and the European Research Council
(ERC) (consolidator grant 819242). CIBERONC was co-funded with FEDER funds and
funded by Instituto de Salud Carlos III (ISCIII). The laboratory of M.C. is supported by
the ERC under the European Union’s Horizon 2020 research and innovation programme
(grant agreement 725004) and CERCA Programme/Generalitat de Catalunya (M.C.).
The laboratory of D.S. is supported by research grants from MINECO (SAF2017-
83813-C3-1-R, also to L.H., cofounded by the ERDF), CIBEROBN (CB06/03/0001),
Government of Catalonia (2017SGR278) and Fundació La Marató de TV3 (201627-
30). The laboratory of R.N. is supported by FEDER/Ministerio de Ciencia, Innovación
y Universidades-Agencia Estatal de Investigación (RTI2018-099413-B-I00 and and
RED2018-102379-T), Xunta de Galicia (2016-PG057 and 2020-PG015), ERC under the
European Union’s Horizon 2020 research and innovation programme (grant agreement
810331), Fundación BBVA, Fundacion Atresmedia and CIBEROBN, which is an
initiative of the ISCIII of Spain, which is supported by FEDER funds. The laboratory
of J.A.V. is supported by research grants from MICINN (RTI2018-099250-B100) and
by La Caixa Foundation (ID 100010434, LCF/PR/HR17/52150009). P.M.G.-R. is
supported by ISCIII grant PI15/00701 cofinanced by the ERDF, A Way to Build
Europe. Personal support was from Marie Curie ITN Actions (E.M.), Juan de la Cierva
(IJCI-2015-23455, P.V.), CONICYT fellowship from Chile (S.Z.), Vetenskapsradet
(Swedish Research Council, 2018-06591, L.G.) and NCI K99/R00 Pathway to
Independence Award (K99CA245122, P. Castel).S
Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure
Anemia is a risk factor related to morbidity and mortality in patients with chronic heart failure (HF). Less is known about its influence in patients in an early stage of HF. Our aim is to investigate the prognostic role of anemia in patients initially hospitalized for acute HF. We reviewed all consecutive patients admitted within a 18-month period with a main diagnosis of acute HF. We collected demographic, clinical and treatment data. Anemia is defined as Hemoglobin <12/13 g/dL upon admission in female/male patients, respectively. 719 patients were included (55.5% female), with a mean age of 78.7 \ub1 9 years. Anemia was present in 59.6% of patients upon admission, with a mean Hb of 10.4 \ub1 1.4 g/dL. Multivariate analysis confirms the relationship between the presence of anemia and older age, a previous diagnostic history of diabetes, and the presence of chronic kidney disease. In-hospital mortality is similar for anemic and non-anemic patients (6.8 vs 3.8%, p = n.s.) However, the difference is significant when one-year mortality is evaluated (31% in anemic patients vs 19% in non-anemic patients, p < 0.001). Cox regression analysis confirms the association between anemia and higher risk of one-year mortality, as well as with older age and a higher Charlson comorbidity index. Our study confirms that the presence of anemia is an independent factor for mid-term (1-year) mortality even in patients experiencing a first admission due to acute HF
Circunstancias asociadas a las caÃdas responsables de fractura de fémur en pacientes mayores de 94 años no institucionalizados
Recommended from our members
PTEN mediates Notch-dependent stalk cell arrest in angiogenesis
Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) specification into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting approaches, here we show that PTEN is crucial for blocking stalk cell proliferation downstream of Notch, and this is critical for mouse vessel development. Endothelial deletion of PTEN results in vascular hyperplasia due to a failure to mediate Notch-induced proliferation arrest. Conversely, overexpression of PTEN reduces vascular density and abrogates the increase in EC proliferation induced by Notch blockade. PTEN is a lipid/protein phosphatase that also has nuclear phosphatase-independent functions. We show that both the catalytic and non-catalytic APC/C-Fzr1/Cdh1-mediated activities of PTEN are required for stalk cells' proliferative arrest. These findings define a Notch–PTEN signalling axis as an orchestrator of vessel density and implicate the PTEN-APC/C-Fzr1/Cdh1 hub in angiogenesis